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ABSTRACT  
Objective: Tumor-necrosis factor (TNF)-α inhibitors including adalimumab have been widely used for patients with inflammatory bowel diseases 
refractory to conventional treatment. Neutropenia is the most common side effect of TNF-α inhibitors, but thrombocytopenia is rarely presented. 
Few cases have been reported on TNF-α-induced thrombocytopenia, but the pathophysiology has not been fully understood. Herein, we explore the 
pathophysiology of adalimumab-induced thrombocytopenia through the clinical course and treatment options for a patient that developed 
thrombocytopenia after administration of adalimumab.  
Methods: We report a singular case of a patient with refractory ulcerative colitis who developed retinal hemorrhages due to thrombocytopenia 
after receiving adalimumab. The patient’s platelet count continued to drop despite discontinuation of adalimumab and platelet transfusion 
administration. Thrombocyopenia stabilized only after receiving intravenous immunoglobulin and prednisone. Laboratory tests identified anti-
platelet IgM, but no antibody reactivity was seen against platelets in the presence of adalimumab (anti-platelet-adalimumab complex). 
Results: The patient’s response to immunosuppressants and lack of antibody against adalimumab-platelet complexes (drug-induced 
thrombocytopenia or type II hypersensitivity reaction) suggests that adalimumab can induce destruction of platelets through the formation anti-
platelet antibodies. This is likely caused by immune system derangement in the setting of a chronic inflammatory state, as seen with ulcerative 
colitis, including an antigenic mimicry of adalimumab against a surface epitope of platelets or adalimumab-induced T-cell apoptosis. 
Conclusion: Physicians are to be aware of a life-threatening complication of adalimumab, immune-mediated thrombocytopenia for the treatment of 
ulcerative colitis. 
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INTRODUCTION 
The release of tissue necrosis factor (TNF)-α is important in the 
pathophysiology of inflammatory diseases such as rheumatoid 
arthritis, seronegative spondyloarthropathies, Crohn’s disease, and 
ulcerative colitis [1-3]. The FDA has approved five TNF-α inhibitors 
for the treatment of a variety of inflammatory illnesses-etanercept, 
infliximab, adalimumab, certolizumab pegol, and golimumab. 
Treatment for ulcerative colitis primarily involves 5-
aminosalicylates or azathioprine but can include TNF-α inhibitors if 
the disease fails to respond to those treatments. Adverse effects of 
TNF-α inhibitors includes anaphylactic reactions, infection, 
lymphoma, thrombocytopenia, congestive heart failure, lupus-like 
syndrome, and demyelinating disease [4]. The most common 
adverse hematological side effect is neutropenia [5]. Therefore, TNF-
α inhibitors are not recommended for patients with active bacterial, 
viral, or fungal infections [6].  
Thrombocytopenia is a rarely reported adverse effect of TNF-α 
inhibitors. Few cases have been reported on TNF-α-induced 
thrombocytopenia, but the risk factors for, and underlying 
mechanism of, TNF-α inhibitor-induced thrombocytopenia are 
poorly understood. As TNF-α inhibitors come into increasing use, it 
is important to understand adverse events and pathophysiology.  
Herein, we report a case of a patient with refractory ulcerative colitis 
who developed thrombocytopenia and retinal hemorrhage after 
treatment with adalimumab. We discuss the patient’s clinical course 
and the pathophysiology of adalimumab-induced thrombocytopenia.  
Case report 
A 26 year-old man with a past medical history of ulcerative colitis, 
diagnosed three and a half years ago via colonoscopy and biopsy 
presented for bilateral constant blurry vision in the context of 
recently starting adalimumab. The patient began treatment with 4.8 
g of mesalamine each day, which initially reduced his symptoms. 
However, the patient was started on azathioprine because of his 
worsening symptoms. As the patient’s symptoms were not 
controlled by the addition of azathioprine, it was discontinued, and 
the patient was started on infliximab.  
The patient’s symptoms underwent remission with infliximab, but 
he began to experience a cascade of side effects including severe 
joint pain in the bilateral lower extremities and shortness of breath. 
As the side effects became debilitating and thought to be secondary 
to a delayed infusion reaction, infliximab was discontinued. At this 
point, laboratory work did not show any evidence of 
thrombocytopenia. The patient remained free of any standing 
medications for two years and received mesalamine and steroids for 
any acute flares.  
The patient’s symptoms gradually worsened. Two and one-half 
months before presentation, the patient resumed medical treatment 
with adalimumab administered subcutaneously every two to three 
weeks. At this point, the patient’s symptoms improved. His platelet 
count was 207,000/mm3. Twenty days after the last dose of 
adalimumab, the patient experienced constant bilateral blurry vision 
on wakening with no other neurological symptoms. He was found to 
have superficial bilateral retinal hemorrhages with a platelet count 
of 3,000/mm3
The patient was admitted to the hospital with an unremarkable 
physical initial examination. He was found to have a hemoglobin of 
0.41 mmol/l (7.4 g/dL), mean corpuscular volume of 78-79 fL, iron 
of 1,020.8 nmol/l (37 µg/dL), ferritin of 5 ng/ml, and total iron 
binding capacity of 7,449.3 nmol/l (270 µg/dL). The patient received 
two units of platelet transfusion, which increased the platelet count 
to 25,000/mm
 in the office of the patient’s primary retinal specialist.  
3 (see fig. 1 for platelet counts after admission). The 
International Journal of Pharmacy and Pharmaceutical Sciences 
ISSN- 0975-1491                 Vol 7, Issue 7, 2015 
Innovare 
Academic Sciences 
Lee et al. 
Int J Pharm Pharm Sci, Vol 7, Issue 7, 456-458 
457 
patient’s platelets dropped again to 8,000/mm3the next day. He 
received another two units of platelets, which again, temporarily 
increased his platelet count to 29,000/mm3. It subsequently 
dropped to 7,000/mm3 and a peripheral blood smear demonstrated 
giant platelets (fig. 2a and b).  
To explore the possibility and pathophysiology of thrombo cytopenia, 
various blood tests were performed. Laboratory studies identified an 
anti-platelet IgM antibody, but no antibody reactivity against platelets 
in the presence of infliximab and adalimumab (antibody against 
platelet-infliximab and platelet-adalimumab complexes) were 
detected. Anti-nuclear antibody, anti-DNA antibody, and anti-
cardiolipin antibody all tested negative. Thyroid stimulating hormone, 
vitamin B12, and folic acid level was within normal limits. Human 
immunodeficiency virus (HIV) test, Helicobacter pylori antigen, and 
hepatitis C antibody was negative. A direct antiglobulin test (DAT) was 
negative, and bilirubin, haptoglobin, and lactate dehydrogenase (LDH) 
levels were within normal limits.  
With a leading diagnosis of immune-mediated thrombocytopenia, 
the patient received 1 g/kg of intravenous immunoglobulin (IVIG) 
for two days along with another two units of platelet transfusion. 
The platelet count was maintained between 10,000-17,000/mm3. A 
second peripheral smear demonstrated more giant platelets and 
appreciable rouleaux formation (fig. 2c and d).  
The rouleaux formation was considered a result of IVIG. The patient 
was started on 1 mg/kg prednisone each day. On the third day of 
prednisone treatment, the patient’s platelet count rose to 
55,000/mm3and was maintained at 20,000–50,000/mm3 (fig. 2e and 
f). The patient’s platelet count remained stable on prednisone, and 
the patient was discharged with a platelet count of 46,000/mm3. 
Two months later, his platelet count was 190,000/mm3
 
on a 
prednisone taper.  
 
Fig. 1: Platelet counts after hospital admission. The patient 
received 2 units of platelet transfusion on hospital day 1, 3, and 
5; intravenous immunoglobulin, on day 5 and 6; and 
prednisone was started on day 7 
 
DISCUSSION 
TNF-α inhibitors often cause neutropenia, but only a few cases of 
thrombocytopenia have been reported with no clear 
pathophysiology. This patient received infliximab and adalimumab, 
but developed thrombocytopenia only after receiving adalimumab. 
Secondary immune thrombocytopenia (ITP) was ruled out by 
negative anti-nuclear antibody, anti-DNA antibody, anti-cardiolipin 
antibody, HIV test, Helicobacter pylori test, and hepatitis C antibody, 
as well as thyroid stimulating hormone, vitamin B12, and folic acid 
level within normal limits. Therefore, TNF-α inhibitor-induced 
thrombocytopenia was diagnosed.  
 
Fig. 2: Peripheral blood smears (Wright’s staining) of this patient with adalimumab-induced thrombocytopenia. a and b: Slides with 
platelet count of 3,000/mm3 before any interventions. c and d: Smears after the patient received IVIG 1 g/kg/d for 2 days with platelet 
count of 17,000/mm3. e and f: Smears at discharge after the patient finished IVIG 1 g/kg/d for 2 days, followed by prednisone 70 mg with 
platelet count of 46,000/mm3. Scale bars = 30 µm (x 400) in a, c, and e. Scale bars = 20 µm (x1,000) in b, d, and f 
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The pathophysiology of TNF-α inhibitor-induced 
thrombocytopenia is poorly understood. Three possible 
mechanisms could be suggested: 1) bone marrow suppression and 
destruction of megakaryocytes or stem cells from direct toxicity of 
adalimumab [7,8], 2) formation of antibodies against a new 
epitope on the drug-platelet complex and destruction of platelets 
only in the presence of the drug (drug-induced thrombocytopenia 
(DITP) or type II hypersensitivity reaction) [9, 10], and 3) an 
immune system derangement and associated formation of 
autoantibodies against platelets, which does not require the 
presence of the drug [5, 11]. 
Direct bone marrow toxicity of adalimumab is unlikely to explain 
this parent’s thrombocytopenia. Peripheral blood smears from the 
patient revealed many giant platelets as shown in fig. 2a and b. This 
suggests that the bone marrow was active and trying to compensate 
for an increased rate of destruction of platelets. 
A type II hypersensitivity reaction or DITP is also unlikely; the 
platelet count did not normalize when adalimumab was 
discontinued. In addition, the patient’s serum demonstrated no 
antibody reactivity against platelets in the presence of infliximab or 
adalimumab. Drugs could make a non-covalent binding with 
platelets, creating a new epitope in the drug-platelet complex. 
Antibodies specific for this new epitope do not bind to platelets in 
the absence of the medication. Other medications including 
vancomycin [12] or acetaminophen [13] were reported to develop 
drug-specific antibodies causing DITP. Only when platelets were 
mixed with vancomycin or acetaminophen did antibodies show 
reactivity against platelets.  
Platelet counts continued to drop despite repeated platelet 
transfusions and discontinuation of adalimumab but were held 
constant after receiving IVIG and prednisone. This strongly implies 
that the destruction of platelets did not require the presence of 
adalimumab and that the etiology was immune-mediated. This is 
supported by the presence of anti-platelet IgM.  
This demonstrates a similar pathophysiology to that reported in 
patients who received alemtuzumab for the treatment of multiple 
sclerosis: Cuker et al. [14] reported a distinct form of immune 
thrombocytopenia (ITP-like syndrome) with persistent 
thrombocytopenia despite discontinuation of alemtuzumab, but 
thrombocytopenia resolved after steroid treatment.  
The presence of anti-platelet IgM is most likely a result of immune 
system derangement: an antigenic mimicry of adalimumab against a 
surface epitope of platelets [15] or adalimumab-induced T-cell 
apoptosis and modification [5] in the setting of a chronic 
inflammatory state, such as ulcerative colitis. 
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